BACKGROUND - The incidence and associated factors of loose seed migration were investigated in cohort 1 of the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - The study subjects were 2160 patients, consisting of 1641 patients who underwent permanent iodine-125 seed implantation (PI) and 519 patients who underwent PI combined with external beam radiation therapy (PI + EBRT).
The presence or absence of seed migration to the chest and abdominal/pelvic region was determined.
RESULTS - Seed migration was observed in 22. 7 % of PI group patients and 18. 1 % of PI + EBRT group patients (p = 0. 0276). Migration to the lungs and abdominal/pelvic region was observed in 14. 6 % and 11. 1 % of the patients in the PI group, and 11. 2 % and 8. 5 % of the patients in the PI + EBRT group, respectively. In the PI group, the number of implanted seeds was associated with the seed migration incidence. Neither the PI nor the PI + EBRT group showed any difference in the volume of the prostate receiving 100 % of the prescribed dose (V100 [%]) or the minimal dose received by 90 % of the prostate volume (D90 [Gy]) between the patients with and without seed migration.
CONCLUSIONS - This prospective cohort study investigating the largest number of past cases showed no difference in D90 (Gy) or V100 (%) between seed migration or the absence thereof in both the PI group and PI + EBRT group.
ClinicalTrials. gov: NCT00534196.
Radiation oncology (London, England). 2015 Nov 14*** epublish ***
Masahiro Nakano, Atsunori Yorozu, Shiro Saito, Akitomo Sugawara, Shinichiroh Maruo, Shinsuke Kojima, Takashi Kikuchi, Masanori Fukushima, Takushi Dokiya, Hidetoshi Yamanaka
Department of Urology, Gifu University Graduate School of Medicine, 1-1Yanagito, Gifu-shi, Gifu, 501-1194, Japan. Department of Radiation Oncology, National Hospital Organization, Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan. Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan. Department of Radiation Oncology, Tokai University, Hachioji Hospital, 1838 Ishikawa-machi, Hachioji-shi, Tokyo, 192-0032, Japan. Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan. Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan. Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan. Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan. Department of Radiology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, Tokyo, 101-0062, Japan. Institute of Preventive Medicine, Kurosawa Hospital, 187 Yanakamachi, Takasaki-shi, Gunma, 370-1203, Japan.